[G-protein-coupled receptors plasticity and signalling]
- PMID: 23067421
- DOI: 10.1051/medsci/20122810018
[G-protein-coupled receptors plasticity and signalling]
Abstract
GPCRs represent the largest cell surface receptor family, regulating all physiological functions and thus constitute major drug targets. Until recently, the receptor was believed to work as an ON-OFF switch able to promote activation of all signaling cascades associated with this receptor. The new concept of biased agonism led recently to the notion of functional selectivity of ligands favoring the activation of specific signaling pathways, thus paving the way for developing pathway-specific drugs with increased efficacy and decreased side effects. However, recent publication of new biosensors with high sensitivity probing the first signaling events close to the active receptor and combined with the analysis of the activation of more downstream effectors has challenged the definition of biased agonism. This review highlights the importance of discriminant functional assays for biased ligands screening and the future strategies for pharmacological mapping optimization aiming to select new drugs with enhanced therapeutic effects.
© 2012 médecine/sciences – Inserm / SRMS.
Similar articles
-
The evasive nature of drug efficacy: implications for drug discovery.Trends Pharmacol Sci. 2007 Aug;28(8):423-30. doi: 10.1016/j.tips.2007.06.005. Epub 2007 Jul 19. Trends Pharmacol Sci. 2007. PMID: 17659355 Review.
-
Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance.Trends Pharmacol Sci. 2007 Aug;28(8):438-46. doi: 10.1016/j.tips.2007.06.001. Epub 2007 Jul 13. Trends Pharmacol Sci. 2007. PMID: 17629964 Review.
-
When simple agonism is not enough: emerging modalities of GPCR ligands.Mol Cell Endocrinol. 2011 Jan 15;331(2):241-7. doi: 10.1016/j.mce.2010.07.009. Epub 2010 Jul 21. Mol Cell Endocrinol. 2011. PMID: 20654693 Review.
-
Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor.Mol Pharmacol. 2010 Jan;77(1):1-9. doi: 10.1124/mol.109.060251. Epub 2009 Oct 16. Mol Pharmacol. 2010. PMID: 19837905 Review.
-
Refining efficacy: exploiting functional selectivity for drug discovery.Adv Pharmacol. 2011;62:79-107. doi: 10.1016/B978-0-12-385952-5.00009-9. Adv Pharmacol. 2011. PMID: 21907907 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous